-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On September 30, the official website of CDE showed that the listing application for Peihuaxi hippocampal peptide injection, a new class 1 drug of Hausen Pharmaceuticals, was accepted by the State Food and Drug Administration
Peihuaxi hippocampal peptide is a polyethylene glycol-modified erythropoietin (EPO) mimetic peptide derivative.
Peihuaxi hippocampal peptide structure
Since EPO is necessary in the formation of red blood cells, it can promote the proliferation of red blood cells, increase the total amount of hemoglobin (Hb) in the body, and improve the body's ability to carry oxygen.
According to the PharmaGo database of Pharma’s Rubik’s Cube, Hausen Pharmaceuticals currently has 5 innovative drugs on the market in China, namely hepatitis B drug imitinofovir fumarate, anti-tumor drugs ametinib, flumatinib, and diabetes treatment.
In addition, there are 4 innovative drugs in the Hausen pipeline that are in the phase II/III phase of research.
In addition, Hausen has also achieved rapid filling of R&D pipelines through product introduction